Elevance Health vs Humana

ELV wins this head-to-head comparison against HUM, primarily driven by its superior profitability and more consistent earnings performance. While both companies operate in the healthcare sector and show positive technical momentum, ELV's stronger net profit margin and return on equity present a more compelling investment case. HUM's higher revenue growth is notable, but its significantly lower profitability and recent negative EPS figures raise concerns about its underlying financial health and operational efficiency. ELV's valuation, though slightly lower on a P/E basis, is supported by its better profitability metrics, making it the preferred choice for investors prioritizing financial stability and consistent earnings generation. The analyst community also shows a slightly more favorable view of ELV, with a higher median price target relative to its current trading price.

ELV's superior profitability, evidenced by its higher net profit margin and return on equity, is the decisive factor separating it from HUM. While HUM shows higher revenue growth, ELV demonstrates a greater ability to translate sales into actual profits and deliver value to shareholders, supported by a more attractive valuation and consistent earnings beats.

The outlook for ELV appears more favorable due to its stronger financial foundation and consistent performance. ELV is expected to continue its upward trajectory, supported by its profitability and positive analyst sentiment, with potential for further gains towards its 52-week high. HUM faces a more uncertain outlook; while its revenue growth is impressive, its profitability challenges and higher valuation present significant headwinds. A sustained improvement in HUM's margins and earnings consistency would be necessary to support its current valuation and achieve its price targets. Investors should watch for margin expansion in HUM and continued operational efficiency from ELV.

ELV trades at a P/E ratio of 18.83, which is considerably lower than HUM's P/E of 41.13, suggesting ELV is more attractively valued on this metric. ELV's price is currently trading at $428.43, which is closer to its 52-week high of $436.24 than HUM's price of $432.20 is to its 52-week high of $456.50. ELV is trading above its 20-day EMA ($408.84) and 50-day SMA ($403.11), indicating positive short-to-medium term price action. HUM is also trading above its 20-day EMA ($405.64) and 50-day SMA ($393.00), showing similar positive short-term trends. However, ELV's P/E ratio suggests a more conservative valuation, especially when considering its stronger profitability.

ELV exhibits significantly superior profitability compared to HUM. ELV boasts a net profit margin of 2.47% and a return on equity of 11.13%, indicating efficient operations and strong returns to shareholders. HUM's net profit margin is considerably lower at 0.88%, and its return on equity stands at 6.89%. While both companies have similar return on assets (ELV at 3.83% and HUM at 3.9%), ELV's ability to convert revenue into profit and generate higher returns for its equity holders makes it the more profitable entity.

ELV is displaying strong upward momentum, with its RSI at 67.23 and CCI at 120.77, indicating strong buying interest without being excessively overbought. The stock is trading above its key moving averages, with its price above the 20-day EMA ($408.84) and 50-day SMA ($403.11). HUM also shows positive technicals, with an RSI of 63.52 and CCI of 100.83, suggesting firm momentum. HUM is also trading above its 20-day EMA ($405.64) and 50-day SMA ($393.00). Both stocks are in uptrends, but ELV's slightly higher RSI and CCI suggest a marginally stronger current technical picture.

Analyst sentiment favors ELV, with a median price target of $463, representing a potential upside of approximately 8.1% from its current price. The analyst ratings for ELV are predominantly 'Buy' or 'Strong Buy'. HUM has a more mixed rating distribution, including one 'Sell' rating. The higher concentration of 'Buy' ratings and a more attractive target-to-price ratio for ELV suggest a more positive analyst outlook.

For ELV, a key risk lies in its relatively low net profit margin (2.47%), which could be vulnerable to margin compression if input costs rise or competitive pressures intensify. Despite consistent earnings beats, its revenue growth of 1.4% is modest, indicating limited top-line expansion potential. For HUM, the primary risks stem from its significantly lower profitability (0.88% net margin) and its history of negative EPS, as seen in its February 2026 report. Its higher valuation (P/E of 41.13) amplifies the risk associated with its less consistent earnings and lower profitability. Also, HUM's higher revenue growth rate of 26.2% may be difficult to sustain if profitability does not improve.